BackInVivo Therapeutics Holdings Overview
InVivo Therapeutics Holdings Corp

InVivo Therapeutics Holdings Return on Equity

InVivo Therapeutics Holdings (NVIV) has a ROE of -100.73%, below the Healthcare sector average of 29.33%.

Get informed when a big investor buys or sells

+ Follow

ROE

-100.73%

Return on Equity

-100.73%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

Average ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

InVivo Therapeutics Holdings (NVIV) FAQ

The latest ROE for NVIV is -100.73%. That is below the Healthcare sector average of 29.33%. Investors often review this figure alongside InVivo Therapeutics Holdings's historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, NVIV currently prints -100.73% for ROE, while the sector average sits near 29.33%. That is roughly 443.4% below the sector mean. Large gaps often invite a closer look at InVivo Therapeutics Holdings's growth, margins, and balance sheet.

Return on Equity shows how effectively InVivo Therapeutics Holdings converts resources into returns. At -100.73%, NVIV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NVIV's ROE (-100.73%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack InVivo Therapeutics Holdings's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.